Related Experiment Video

Updated: Jun 19, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec

Kristen N Ganjoo, George D Demetri, Charlotte Jacobs

    Leukemia & Lymphoma
    |November 4, 2009
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
    07:21

    Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

    Published on: May 2, 2022

    Related Experiment Videos

    Last Updated: Jun 19, 2026

    Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
    06:43

    Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

    Published on: April 3, 2026

    Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
    07:21

    Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

    Published on: May 2, 2022

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.

    Cancer·2026

    A Multicenter Retrospective Outcomes Analysis of Patients with Localized Synovial Sarcoma.

    Cancer research communications·2026

    Efficacy and Safety of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Uterine Leiomyosarcoma: Results of a Phase 2 Study.

    Annals of surgical oncology·2026

    Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

    Nature communications·2026

    NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

    Journal of the National Comprehensive Cancer Network : JNCCN·2026

    Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

    Science translational medicine·2026

    Clinical outcomes with azole and other CYP3A4 inhibitor coadministration during venetoclax plus azacitidine or decitabine therapy in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.

    Leukemia & lymphoma·2026

    Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies.

    Leukemia & lymphoma·2026

    Evaluating YouTube videos for Hodgkin lymphoma patient education.

    Leukemia & lymphoma·2026

    Venetoclax consolidation deepens response and enables measurable residual disease-guided finite therapy in BTK inhibitor-treated chronic lymphocytic leukemia.

    Leukemia & lymphoma·2026

    Clinical outcomes of adults with PAX5-mutated or rearranged B-cell acute lymphoblastic leukemia.

    Leukemia & lymphoma·2026

    Efficacy and safety of three-drug induction-based MASPORE 2003 chemotherapy protocol in standard- and intermediate-risk pediatric acute lymphoblastic leukemia: a decade-long single-center experience from India.

    Leukemia & lymphoma·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us